Comparison between Colistin and Polymyxin B in the Treatment of Bloodstream Infections Caused by Carbapenem-Resistant Pseudomonas aeruginosa and Acinetobacter baumannii-calcoaceticus Complex

Detalhes bibliográficos
Autor(a) principal: Garcia, Rebeca Carvalho Lacerda
Data de Publicação: 2023
Outros Autores: Rodrigues, Rodrigo Douglas, Garcia, Ester Carvalho Lacerda, Rigatto, Maria Helena da Silva Pitombeira
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Repositório Institucional da UFRGS
Texto Completo: http://hdl.handle.net/10183/280250
Resumo: Polymyxins are still widely used for the treatment of carbapenem-resistant Acinetobacter baumannii and Pseudomonas aeruginosa bloodstream infections (BSIs). This study seeks to evaluate the impact of polymyxin B versus colistin on mortality and nephrotoxicity in BSI caused by these bacteria. We conducted a retrospective cohort study from 2014 to 2021 in Porto Alegre, Brazil. We included patients aged ≥18 years and excluded patients with polymicrobial infection or treatment for ≤48 h. The 30-day mortality was the primary outcome evaluated through Cox regression. We included 259 patients with BSI episodes: 78.8% caused by A. baumannii and 21.2% caused by P. aeruginosa. Polymyxin B did not impact mortality compared to colistin (adjusted hazard ratio (aHR), 0.82; 95% confidence interval (CI), 0.52-1.30; p = 0.40 (when adjusted for COVID-19 comorbidity, p = 0.05), Pitt bacteremia score, p < 0.01; Charlson comorbidity index, p < 0.001; time to start active antimicrobial therapy, p = 0.02). Results were maintained in the subgroups of BSI caused by A. baumannii (aHR, 0.92; 95% CI, 0.55-1.54; p = 0.74), P. aeruginosa (aHR, 0.47; 95% CI, 0.17-1.32; p = 0.15) and critical care patients (aHR, 0.77; 95% CI, 0.47-1.26; p = 0.30). Treatment with polymyxin B or colistin did not impact 30-day mortality in patients with carbapenem-resistant A. baumannii or P. aeruginosa BSI.
id UFRGS-2_7dc4b290eca7960e395e8b11d50aaafe
oai_identifier_str oai:www.lume.ufrgs.br:10183/280250
network_acronym_str UFRGS-2
network_name_str Repositório Institucional da UFRGS
repository_id_str
spelling Garcia, Rebeca Carvalho LacerdaRodrigues, Rodrigo DouglasGarcia, Ester Carvalho LacerdaRigatto, Maria Helena da Silva Pitombeira2024-10-19T06:18:52Z20232079-6382http://hdl.handle.net/10183/280250001206250Polymyxins are still widely used for the treatment of carbapenem-resistant Acinetobacter baumannii and Pseudomonas aeruginosa bloodstream infections (BSIs). This study seeks to evaluate the impact of polymyxin B versus colistin on mortality and nephrotoxicity in BSI caused by these bacteria. We conducted a retrospective cohort study from 2014 to 2021 in Porto Alegre, Brazil. We included patients aged ≥18 years and excluded patients with polymicrobial infection or treatment for ≤48 h. The 30-day mortality was the primary outcome evaluated through Cox regression. We included 259 patients with BSI episodes: 78.8% caused by A. baumannii and 21.2% caused by P. aeruginosa. Polymyxin B did not impact mortality compared to colistin (adjusted hazard ratio (aHR), 0.82; 95% confidence interval (CI), 0.52-1.30; p = 0.40 (when adjusted for COVID-19 comorbidity, p = 0.05), Pitt bacteremia score, p < 0.01; Charlson comorbidity index, p < 0.001; time to start active antimicrobial therapy, p = 0.02). Results were maintained in the subgroups of BSI caused by A. baumannii (aHR, 0.92; 95% CI, 0.55-1.54; p = 0.74), P. aeruginosa (aHR, 0.47; 95% CI, 0.17-1.32; p = 0.15) and critical care patients (aHR, 0.77; 95% CI, 0.47-1.26; p = 0.30). Treatment with polymyxin B or colistin did not impact 30-day mortality in patients with carbapenem-resistant A. baumannii or P. aeruginosa BSI.application/pdfengAntibiotics. Basel. Vol. 12, no. 8 (2023), 1317, 12 p.Polimixina BAcinetobacter baumanniiPseudomonas aeruginosaSepseColistinaPseudomonas aeruginosaBloodstream infectionColistinPolymyxin BComparison between Colistin and Polymyxin B in the Treatment of Bloodstream Infections Caused by Carbapenem-Resistant Pseudomonas aeruginosa and Acinetobacter baumannii-calcoaceticus ComplexEstrangeiroinfo:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/openAccessreponame:Repositório Institucional da UFRGSinstname:Universidade Federal do Rio Grande do Sul (UFRGS)instacron:UFRGSTEXT001206250.pdf.txt001206250.pdf.txtExtracted Texttext/plain46946http://www.lume.ufrgs.br/bitstream/10183/280250/2/001206250.pdf.txt65ae3b0dde39a52b45310a3992d5e6cfMD52ORIGINAL001206250.pdfTexto completo (inglês)application/pdf840652http://www.lume.ufrgs.br/bitstream/10183/280250/1/001206250.pdf3f1bf17b717b64aed10cba37fe286360MD5110183/2802502024-10-20 06:56:45.82665oai:www.lume.ufrgs.br:10183/280250Repositório de PublicaçõesPUBhttps://lume.ufrgs.br/oai/requestopendoar:2024-10-20T09:56:45Repositório Institucional da UFRGS - Universidade Federal do Rio Grande do Sul (UFRGS)false
dc.title.pt_BR.fl_str_mv Comparison between Colistin and Polymyxin B in the Treatment of Bloodstream Infections Caused by Carbapenem-Resistant Pseudomonas aeruginosa and Acinetobacter baumannii-calcoaceticus Complex
title Comparison between Colistin and Polymyxin B in the Treatment of Bloodstream Infections Caused by Carbapenem-Resistant Pseudomonas aeruginosa and Acinetobacter baumannii-calcoaceticus Complex
spellingShingle Comparison between Colistin and Polymyxin B in the Treatment of Bloodstream Infections Caused by Carbapenem-Resistant Pseudomonas aeruginosa and Acinetobacter baumannii-calcoaceticus Complex
Garcia, Rebeca Carvalho Lacerda
Polimixina B
Acinetobacter baumannii
Pseudomonas aeruginosa
Sepse
Colistina
Pseudomonas aeruginosa
Bloodstream infection
Colistin
Polymyxin B
title_short Comparison between Colistin and Polymyxin B in the Treatment of Bloodstream Infections Caused by Carbapenem-Resistant Pseudomonas aeruginosa and Acinetobacter baumannii-calcoaceticus Complex
title_full Comparison between Colistin and Polymyxin B in the Treatment of Bloodstream Infections Caused by Carbapenem-Resistant Pseudomonas aeruginosa and Acinetobacter baumannii-calcoaceticus Complex
title_fullStr Comparison between Colistin and Polymyxin B in the Treatment of Bloodstream Infections Caused by Carbapenem-Resistant Pseudomonas aeruginosa and Acinetobacter baumannii-calcoaceticus Complex
title_full_unstemmed Comparison between Colistin and Polymyxin B in the Treatment of Bloodstream Infections Caused by Carbapenem-Resistant Pseudomonas aeruginosa and Acinetobacter baumannii-calcoaceticus Complex
title_sort Comparison between Colistin and Polymyxin B in the Treatment of Bloodstream Infections Caused by Carbapenem-Resistant Pseudomonas aeruginosa and Acinetobacter baumannii-calcoaceticus Complex
author Garcia, Rebeca Carvalho Lacerda
author_facet Garcia, Rebeca Carvalho Lacerda
Rodrigues, Rodrigo Douglas
Garcia, Ester Carvalho Lacerda
Rigatto, Maria Helena da Silva Pitombeira
author_role author
author2 Rodrigues, Rodrigo Douglas
Garcia, Ester Carvalho Lacerda
Rigatto, Maria Helena da Silva Pitombeira
author2_role author
author
author
dc.contributor.author.fl_str_mv Garcia, Rebeca Carvalho Lacerda
Rodrigues, Rodrigo Douglas
Garcia, Ester Carvalho Lacerda
Rigatto, Maria Helena da Silva Pitombeira
dc.subject.por.fl_str_mv Polimixina B
Acinetobacter baumannii
Pseudomonas aeruginosa
Sepse
Colistina
topic Polimixina B
Acinetobacter baumannii
Pseudomonas aeruginosa
Sepse
Colistina
Pseudomonas aeruginosa
Bloodstream infection
Colistin
Polymyxin B
dc.subject.eng.fl_str_mv Pseudomonas aeruginosa
Bloodstream infection
Colistin
Polymyxin B
description Polymyxins are still widely used for the treatment of carbapenem-resistant Acinetobacter baumannii and Pseudomonas aeruginosa bloodstream infections (BSIs). This study seeks to evaluate the impact of polymyxin B versus colistin on mortality and nephrotoxicity in BSI caused by these bacteria. We conducted a retrospective cohort study from 2014 to 2021 in Porto Alegre, Brazil. We included patients aged ≥18 years and excluded patients with polymicrobial infection or treatment for ≤48 h. The 30-day mortality was the primary outcome evaluated through Cox regression. We included 259 patients with BSI episodes: 78.8% caused by A. baumannii and 21.2% caused by P. aeruginosa. Polymyxin B did not impact mortality compared to colistin (adjusted hazard ratio (aHR), 0.82; 95% confidence interval (CI), 0.52-1.30; p = 0.40 (when adjusted for COVID-19 comorbidity, p = 0.05), Pitt bacteremia score, p < 0.01; Charlson comorbidity index, p < 0.001; time to start active antimicrobial therapy, p = 0.02). Results were maintained in the subgroups of BSI caused by A. baumannii (aHR, 0.92; 95% CI, 0.55-1.54; p = 0.74), P. aeruginosa (aHR, 0.47; 95% CI, 0.17-1.32; p = 0.15) and critical care patients (aHR, 0.77; 95% CI, 0.47-1.26; p = 0.30). Treatment with polymyxin B or colistin did not impact 30-day mortality in patients with carbapenem-resistant A. baumannii or P. aeruginosa BSI.
publishDate 2023
dc.date.issued.fl_str_mv 2023
dc.date.accessioned.fl_str_mv 2024-10-19T06:18:52Z
dc.type.driver.fl_str_mv Estrangeiro
info:eu-repo/semantics/article
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://hdl.handle.net/10183/280250
dc.identifier.issn.pt_BR.fl_str_mv 2079-6382
dc.identifier.nrb.pt_BR.fl_str_mv 001206250
identifier_str_mv 2079-6382
001206250
url http://hdl.handle.net/10183/280250
dc.language.iso.fl_str_mv eng
language eng
dc.relation.ispartof.pt_BR.fl_str_mv Antibiotics. Basel. Vol. 12, no. 8 (2023), 1317, 12 p.
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.source.none.fl_str_mv reponame:Repositório Institucional da UFRGS
instname:Universidade Federal do Rio Grande do Sul (UFRGS)
instacron:UFRGS
instname_str Universidade Federal do Rio Grande do Sul (UFRGS)
instacron_str UFRGS
institution UFRGS
reponame_str Repositório Institucional da UFRGS
collection Repositório Institucional da UFRGS
bitstream.url.fl_str_mv http://www.lume.ufrgs.br/bitstream/10183/280250/2/001206250.pdf.txt
http://www.lume.ufrgs.br/bitstream/10183/280250/1/001206250.pdf
bitstream.checksum.fl_str_mv 65ae3b0dde39a52b45310a3992d5e6cf
3f1bf17b717b64aed10cba37fe286360
bitstream.checksumAlgorithm.fl_str_mv MD5
MD5
repository.name.fl_str_mv Repositório Institucional da UFRGS - Universidade Federal do Rio Grande do Sul (UFRGS)
repository.mail.fl_str_mv
_version_ 1815447867882471424